Global Metagenomics Market Size

Metagenomics Market Analysis

The metagenomics market is expected to register a CAGR of 12.6% over the forecast period, 2022-2027.

The COVID-19 pandemic is expected to have shifted the focus to the growth of the metagenomics market. Metagenomics is widely used in analyzing the interactions between the microbiome and various pathological interventions associated with COVID-19 infection. Metagenomic next-generation sequencing (mNGS) is one of the advanced techniques in detecting SARS-CoV-2 from nasopharyngeal (NP) swabs and also provides information on the composition of the microbiome in the upper respiratory tract and aids in analyzing its relationship to coinfections or the presence of other organisms that may impact SARS-CoV-2 disease progression and prognosis. According to the research article titled' Metagenomics: preventing future pandemics' published in Future Science, 2021, pandemic risk calculations make use of technologies such as metagenomics to trace the molecular changes in pathogens during their emergence globally, which could assist in the prediction of hotspots of emergence, populations at risk, and the pathogens under genetic evolution. Thus, given the aforementioned factors, the COVID-19 pandemic is expected to have a significant impact on the metagenomics market.

Increasing awareness about metagenomics is attributed to the increasing Research and development expenditure, declining expenses of sequencing, and technological advancements. Besides, the growing interest of researchers in the field of metatranscriptomics, metabolomics, and metaproteomic and investments in bioinformatics to promote metagenomics and microbiome profiling are also some of the factors propelling the growth of the market. for instace, in January 2022 SeqOne company raised EUR 20 Million in a Series A round as growing investments reach startups delivering the next generations of genomics and bioinformatics. Moreover, as DNA sequencing is highly associated with metagenomics, the technological advancement in the field of DNA sequencing results in several advantages compared to conventional methods. The features of accuracy, reducing the number of pre-sequencing, and reliability on sequencing have added to increased dependence on the technology in metagenomics. Hence, the advancements in DNA sequencing are expected to propel the market for metagenomics in the coming years. Furthermore, rising concerns related to viral diseases such as virus-induced diarrhea, influenza, hepatitis B, and HIV/AIDS and a growing number of genes being identified have led to the development of novel metagenome study products. According to United Nations AIDS, 2022, 37.7 million people globally were living with HIV. 79.3 million people have become infected with HIV since the start of the epidemic. New HIV infections have been reduced by 52%. And around 1.5 million people were newly infected with HIV.

Thus the above mentioned factors are expected to drive the growth of the market during the forecast period. However, the high cost of overall metagenomics may hamper the market to a certain extent.